title: Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome.
abstract: In this study we demonstrate that IgG present in the sera of patients with primary Sjögren's syndrome (PSS) could bind and activate muscarinic acetylcholine receptors (mAChRs) of rat parotid gland. These antibodies were able to inhibit in a non-competitive manner the binding of 3H-quinuclidinyl benzilate (QNB) to mAChRs of purified rat parotid gland membranes. Moreover, IgG from PSS could modify biological effects mediated by mAChR activation; i.e. decrease cAMP, increase phosphoinositide turnover without affecting cGMP. Atropine and 4-DAMP blocked all of these effects, and carbachol mimicked them, confirming the M3 subtype mAChRs mediated PSS IgG action. Neither binding nor biological effect were obtained with IgG from sera of normal women. The prevalence of cholinergic antibody was 100% in PSS, and was independent of Ro/SS-A and La/SS-B antibodies. It could be concluded that antibody against mAChRs may be another serum factor to be considered in the pathophysiology of the development of PSS.
authors.affiliation: CEFYBO-CONICET, Buenos Aires, Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Bacman
authors.forename: L
authors.initials: L
authors.lastname: Sterin-Borda
authors.forename: J J
authors.initials: JJ
authors.lastname: Camusso
authors.forename: R
authors.initials: R
authors.lastname: Arana
authors.forename: O
authors.initials: O
authors.lastname: Hubscher
authors.forename: E
authors.initials: E
authors.lastname: Borda
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology; D001285:Atropine / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D002219:Carbamates / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology*; D007545:Isoproterenol / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000276:immunology / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010306:Parotid Gland / Q000276:immunology*; D048448:Phenylcarbamates; D010716:Phosphatidylinositols / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011813:Quinuclidinyl Benzilate / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000276:immunology*; D012859:Sjogren's Syndrome / Q000097:blood / Q000276:immunology*
chemical_list: D000318:Adrenergic beta-Agonists; D019138:Antibodies, Blocking; D002219:Carbamates; D007074:Immunoglobulin G; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D048448:Phenylcarbamates; D010716:Phosphatidylinositols; D010880:Piperidines; D011480:Protease Inhibitors; D011976:Receptors, Muscarinic; C025508:2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate; D010890:Pirenzepine; D011813:Quinuclidinyl Benzilate; D001285:Atropine; C042375:4-diphenylacetoxy-1,1-dimethylpiperidinium; D002217:Carbachol; D000242:Cyclic AMP; D006152:Cyclic GMP; D007545:Isoproterenol; C048593:otenzepad